28304102|t|Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors
28304102|a|Signaling pathway inhibition of VEGFR-II is visualized as valuable tool in cancer management. In the current study, the synthesis of novel 1-4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(N-substituted-amino)-ethanone derivatives (4a-t) was achieved through the amination of 2-chloro-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (3) with different secondary amines. The structures of the target compounds were confirmed by IR, (1) H-NMR, (13) C-NMR, HRMS, and microanalysis. Compounds 4a-t were subjected to in vitro anticancer screening against human breast cancer (MCF-7) and prostate cancer (PC3) cell lines. The highest cytotoxicty against both cell lines was displayed by 2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (4q), with IC50 values of 6.502 and 11.751 μM against MCF-7 and PC3 cells, respectively, compared with the standard drug doxorubicin (MCF-7: 6.774 μM, PC3: 7.7316 μM). Due to its notable activity toward MCF-7 cells, 4q was further evaluated as VEGFR-II inhibitor, showing an IC50 of 1.38 μM compared to sorafenib (0.33 μM). The docking study proved that 4q has a binding mode akin to that of VEGFR-II inhibitors.
28304102	23	32	Cytotoxic	T038	UMLS:C0596402
28304102	33	43	Evaluation	T058	UMLS:C0220825
28304102	55	91	7-Chloro-4-(piperazin-1-yl)quinoline	T103	UMLS:C0034424
28304102	92	103	Derivatives	T103	UMLS:C0243072
28304102	107	115	VEGFR-II	T103	UMLS:C0378796
28304102	116	126	Inhibitors	T103	UMLS:C0243077
28304102	127	144	Signaling pathway	T038	UMLS:C0037080
28304102	159	167	VEGFR-II	T103	UMLS:C0378796
28304102	202	208	cancer	T038	UMLS:C0006826
28304102	209	219	management	T058	UMLS:C0376636
28304102	228	241	current study	T062	UMLS:C2603343
28304102	266	341	1-4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(N-substituted-amino)-ethanone	T103	UMLS:C0034424
28304102	342	353	derivatives	T103	UMLS:C0243072
28304102	355	359	4a-t	T103	UMLS:C0034424
28304102	399	463	2-chloro-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (3)	T103	UMLS:C0034424
28304102	479	496	secondary amines.	T103	UMLS:C0002508
28304102	501	511	structures	T082	UMLS:C0026383
28304102	526	535	compounds	T103	UMLS:C1706082
28304102	554	556	IR	T058	UMLS:C0037807
28304102	558	567	(1) H-NMR	T058	UMLS:C3850001
28304102	569	579	(13) C-NMR	T058	UMLS:C3850003
28304102	581	585	HRMS	T058	UMLS:C0037813
28304102	591	604	microanalysis	T058	UMLS:C0013844
28304102	606	615	Compounds	T103	UMLS:C1706082
28304102	616	620	4a-t	T103	UMLS:C0034424
28304102	648	658	anticancer	T058	UMLS:C0920425
28304102	659	668	screening	T058	UMLS:C1710032
28304102	677	696	human breast cancer	T038	UMLS:C0678222
28304102	698	703	MCF-7	T017	UMLS:C0596890
28304102	709	724	prostate cancer	T038	UMLS:C0600139
28304102	726	729	PC3	T017	UMLS:C0007634
28304102	731	741	cell lines	T017	UMLS:C0007600
28304102	755	766	cytotoxicty	T038	UMLS:C0596402
28304102	780	790	cell lines	T017	UMLS:C0007600
28304102	808	900	2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (4q)	T103	UMLS:C0034424
28304102	950	955	MCF-7	T017	UMLS:C0596890
28304102	960	969	PC3 cells	T017	UMLS:C0007634
28304102	1017	1028	doxorubicin	T103	UMLS:C0013089
28304102	1030	1035	MCF-7	T017	UMLS:C0596890
28304102	1047	1050	PC3	T017	UMLS:C0007634
28304102	1099	1110	MCF-7 cells	T017	UMLS:C0596890
28304102	1112	1114	4q	T103	UMLS:C0034424
28304102	1140	1148	VEGFR-II	T103	UMLS:C0378796
28304102	1149	1158	inhibitor	T103	UMLS:C0243077
28304102	1199	1208	sorafenib	T103	UMLS:C1516119
28304102	1224	1231	docking	T038	UMLS:C1522290
28304102	1250	1252	4q	T103	UMLS:C0034424
28304102	1259	1271	binding mode	T038	UMLS:C1167622
28304102	1288	1296	VEGFR-II	T103	UMLS:C0378796
28304102	1297	1307	inhibitors	T103	UMLS:C0243077